| Description | SBI993 is an analog of SBI-477 and can be used as a biomarker to confirm the expected action of MondoA target gene expression in vivo. SBI993 reduces muscle TAG levels and hepatic steatosis. |
| In vitro | SBI-993在人类肌管中降低了TXNIP和ARRDC4的表达[1]。 |
| In vivo | SBI993（50 mg/kg；s.c.）在肌肉和肝脏中降低了TAG合成和脂肪生成基因的表达。尤其在肝脏中，SBI993显著减少了Txnip和Arrdc4的表达。在肝脏中，SBI993减少了ChREBP和MondoA对Txnip和丙酮酸激酶（Pklr）基因启动子的占用[1]。 |
| molecular weight | 453.51 |
| Molecular formula | C23H23N3O5S |
| CAS | 2073059-56-8 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (121.28 mM) |
| References | 1. Byungyong Ahn, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79. |